NasdaqHealth CarePharmaceutical PreparationsTORONTO, Ontario, Canada

ProMIS Neurosciences Inc. PMN

Ask your AI

Estimated market cap $29.60M9.00M shares, shares as of Nov 12, 2026CIK 1374339

Insider trades, 12 mo

11 buys · 0 sells

$8.88M bought, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q2 2026

71.2% of shares · 6 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in ProMIS Neurosciences Inc.'s latest quarterly report, compared with the one before.

Filed Nov 12, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in ProMIS Neurosciences Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

11 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Recent insider trades

Eugene Williams Director	Nov 4 Form 4 ↗	Buy	+$90.9K 26,500 sh @ $3.43	-4.9%
Neil Cashman Chief Scientific Officer, Director	Nov 2 Form 4 ↗	Buy	+$38.6K 10,000 sh @ $3.86	+9.4%
Eugene Williams Director	Oct 30 Form 4 ↗	Buy	+$5,251 1,316 sh @ $3.99	-0.4%
Johanne Kaplan Chief Development Officer	Aug 5 Form 4 ↗	Buy	+$30.3K 2,280 sh @ $13.30	-73.6%
Patrick D. Kirwin Director	Apr 22 Form 4 ↗	Buy	+$45.3K 4,000 sh @ $11.33	-76.5%

All PMN insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

6.40M shares

27 funds report PMN. Values checked against market prices.

Funds own 71% of shares (Q2 2026)

27 funds hold the stock.

Q3 2026: 0.4% · 5,560 of ~8,900 funds reported so far

Q4 202512%
Q1 202669%
Q2 202671%
Q3 2026 (so far)0.4%

Reports for the quarter ending Sep 30, 2026 are still coming in (8 positions so far, against 27 the quarter before), so we compare the two complete quarters before it.

Q2 2026. 5 new, 6 added to, 6 trimmed, 3 exited since Q1 2026.

Top 13F holders
#
1	Jupiter Topco LLC 13F ↗	1.29M	$17.0M	New
2	Deep Track Capital, LP 13F ↗	835,655	$11.0M	unchanged
3	Wellington Management Group LLP 13F ↗	696,378	$9.2M	unchanged
4	Ally Bridge Group (NY) LLC 13F ↗	620,319	$8.2M	+49.8%
5	Trails Edge Capital Partners, LP 13F ↗	557,103	$7.3M	unchanged
6	Woodline Partners LP 13F ↗	441,911	$5.8M	+11.8%
7	Yu Fan 13F ↗	329,760	$4.3M	unchanged
8	Sphera Funds Management Ltd. 13F ↗	325,591	$4.3M	unchanged
9	Squadron Capital Management LLC 13F ↗	324,977	$4.3M	unchanged
10	Ikarian Capital, LLC 13F ↗	205,000	$2.7M	+272.7%

Download CSV Every fund that holds PMN, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What ProMIS Neurosciences Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What ProMIS Neurosciences Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q4 2025	9	—	264,549	$1.8M
Q1 2026	25	+16	6.14M	$78.0M
Q2 2026	27	+2	6.40M	$84.3M
Q3 2026	8	-19	34,545	$374.8K

Each point is a quarter-end, from Q4 2025 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (74346M505). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q4 2025) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes16 in 12 mo 8-K events2 in 90 days Patents2 patents granted Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials1 active IPO history1 registration Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: ProMIS Neurosciences Inc.
Address: SUITE 200, 1920 YONGE STREET, TORONTO, Ontario, Canada M4S 3E2
Phone: 416-847-6898
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company, emerging growth company
Incorporated in: Canada (Federal Level)
Listed as: PMN (Nasdaq)
Former names: AMORFIX LIFE SCIENCES LTD (until 2014)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$3.29−$0.19 (−5.46%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $3.00 · High $11.08Nov 13, 2026

Aug 13, 2026Low $3.00 · High $15.36Nov 13, 2026

Nov 13, 2025Low $3.00 · High $24.79Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. The stock split 1-for-25 on Nov 28, 2025; earlier prices are shown divided by the split ratio. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.